Sepsis-induced increases in glucose uptake by macrophage-rich tissues persist during hypoglycemia.
The purpose of the present study was to determine how hypoglycemia alters glucose uptake by individual tissues and whether this response is altered by gram-negative infection. A hypermetabolic septic state was produced in catheterized rats by subcutaneous injections of live Escherichia coli. The next morning, animals were infused with saline, somatostatin to produce a euglycemic insulinopenic state (6 mmol/L glucose, 5 microU/mL insulin), or 3-mercaptopicolinate (3-MP) to inhibit gluconeogenesis and produce a hypoglycemic insulinopenic (4.5 or 2 mmol/L glucose, 5 microU/mL insulin) condition. After 140 minutes, [14C]2-deoxyglucose was injected intravenously (IV) to determine in vivo glucose uptake by individual tissues. Sepsis increased whole body glucose disposal (Rd) by 53% under basal euglycemic conditions and this increase resulted from an enhanced rate of glucose removal by liver, spleen, lung, ileum, and skin. Under euglycemic insulinopenic conditions, total glucose Rd decreased in both septic and nonseptic rats as a result of a decreased rate of glucose uptake by muscle. However, because the absolute rate of glucose uptake was still elevated by sepsis, the rate of non-insulin-mediated glucose uptake (NIMGU) was 46% higher in septic rats than in nonseptic animals. Severe hypoglycemia (2 mmol/L) produced a relative insulin deficiency and decreased whole body Rd in both septic and nonseptic animals by 53% to 58%, compared with euglycemic insulinopenic animals. The decrease in blood glucose decreased glucose uptake by all tissues examined, except brain and heart. However, sepsis still increased glucose uptake by liver, spleen, lung, ileum, and skin (25% to 90%), compared with hypoglycemic nonseptic rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Lang
C H
CH
Department of Physiology, Louisiana State University Medical Center, New Orleans 70112.
Dobrescu
C
C
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003847:Deoxyglucose / Q000378:metabolism*; D004927:Escherichia coli Infections / Q000150:complications / Q000378:metabolism*; D005934:Glucagon / Q000097:blood; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D015309:Glucose Clamp Technique; D007003:Hypoglycemia / Q000150:complications / Q000378:metabolism*; D007328:Insulin / Q000097:blood*; D007700:Kinetics; D007773:Lactates / Q000097:blood; D008297:Male; D009928:Organ Specificity; D010848:Picolinic Acids / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D018805:Sepsis / Q000150:complications / Q000378:metabolism*; D013004:Somatostatin / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; D007773:Lactates; D010848:Picolinic Acids; D013004:Somatostatin; C008363:3-mercaptopicolinic acid; D005934:Glucagon; D003847:Deoxyglucose; D005947:Glucose